Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

Background: Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem cells and tumor vasculature.Objective: This phase IB trial of demcizumab, an IgG2 humanized monoclonal antibody directed against DLL4, was undertaken to determine its max...

Full description

Bibliographic Details

Published in:	Targeted Oncology Vol. 13; no. 1; pp. 89 - 99
Main Authors:	McKeage, Mark J., Kotasek, Dusan, Markman, Ben, Hidalgo, Manuel, Millward, Michael J., Jameson, Michael B., Harris, Dean L., Stagg, Robert J., Kapoun, Ann M., Xu, Lu, Hughes, Brett G. M.
Format:	research Journal Article
Published:	Springer Nature Feb2018
Online Access:	View this record in EBSCOhost